Peptide Drugs for Female Sexual Dysfunction: The Evidence
Female Sexual Response Peptides
1.2 point increase
In sexual desire scores (on a 1-5 scale) among premenopausal women treated with bremelanotide vs. 0.8 points for placebo in two Phase 3 trials of 1,247 women.
Kingsberg et al., Obstetrics & Gynecology, 2019
Kingsberg et al., Obstetrics & Gynecology, 2019
View as imageFemale sexual dysfunction affects an estimated 40% of women at some point in their lives, but only a fraction meet criteria for hypoactive sexual desire disorder (HSDD), the persistent absence of sexual desire that causes personal distress. For decades, the pharmaceutical approach to female sexual dysfunction lagged far behind treatments for male erectile dysfunction. Peptides have changed that conversation. Bremelanotide (Vyleesi), a synthetic melanocortin receptor agonist, became the first and only FDA-approved peptide drug for HSDD in 2019. Kisspeptin and oxytocin are in earlier stages of clinical testing. This article evaluates what the data actually shows for each peptide, including the limitations the marketing materials leave out. For the broader science of how peptides interact with female sexual response, see Oxytocin and Female Sexual Response: The Bonding-Arousal Connection.
Key Takeaways
- Bremelanotide increased desire scores by 1.2 points vs. 0.8 for placebo (on a 1-5 scale) in two Phase 3 trials of 1,247 premenopausal women with HSDD[6]
- Nausea affected 40% of bremelanotide users vs. 1% on placebo, and 18% discontinued treatment due to side effects[6]
- A reanalysis of bremelanotide Phase 3 data questioned the clinical meaningfulness of the statistical improvements[8]
- Kisspeptin reduced self-monitoring brain activity and increased sexual arousal processing in a 2022 RCT of 32 women with HSDD[9]
- Intranasal oxytocin improved sexual function scores in premenopausal but not postmenopausal women in one randomized trial[5]
- All three peptides work through the central nervous system rather than genital blood flow, a fundamentally different mechanism than drugs for male sexual dysfunction
How Peptides Approach Female Sexual Desire
Female sexual desire originates in the brain, not the genitals. This is why drugs that increase genital blood flow (the mechanism behind sildenafil for men) have consistently failed in women. The peptides being studied for female sexual dysfunction all work centrally, in the hypothalamus and limbic system, where desire, arousal, and emotional processing converge.
The melanocortin system was identified as a regulator of sexual function when researchers developing melanocortin-based tanning peptides noticed an unexpected side effect: spontaneous erections in male subjects.[2] Follow-up work by Hadley (2005) established that melanocortin receptors (MC3R and MC4R) in the hypothalamus mediate sexual arousal in both sexes.[2] This discovery led directly to the development of bremelanotide.
Kisspeptin operates through a different pathway. It acts on the hypothalamic-pituitary-gonadal axis as the master regulator of reproductive hormones, but brain imaging studies have revealed it also modulates limbic processing of sexual stimuli, reducing inhibitory self-monitoring and enhancing arousal-related brain activation.[9]
Oxytocin, produced in the hypothalamus and released during physical intimacy, plays a role in bonding, trust, and the subjective experience of sexual pleasure. Its relationship to sexual desire is less direct than melanocortins or kisspeptin. For the full picture of kisspeptin's neuroimaging evidence, see Kisspeptin and Female Sexual Arousal: Neuroimaging Evidence.
Bremelanotide: What the Phase 3 Trials Found
Bremelanotide (originally PT-141, marketed as Vyleesi) is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone. It activates MC3R and MC4R in the hypothalamus, increasing dopaminergic signaling in brain regions associated with sexual motivation.[10]
The RECONNECT program comprised two identical Phase 3, randomized, double-blind, placebo-controlled trials enrolling 1,247 premenopausal women with acquired, generalized HSDD. Participants self-administered 1.75 mg bremelanotide subcutaneously as needed, at least 45 minutes before anticipated sexual activity.[6]
Both trials met their coprimary endpoints. On the Female Sexual Function Index desire domain (scored 1.2 to 6.0), bremelanotide increased desire scores by 0.5 points more than placebo. On a distress scale measuring how much low desire bothered patients, bremelanotide reduced distress by 0.3 points more than placebo. Both differences were statistically significant.[6]
Early clinical work by Diamond and colleagues (2006) had shown that bremelanotide increased subjective sexual arousal in premenopausal women with sexual arousal disorder, establishing the proof-of-concept for the Phase 3 program.[3]
The Clinical Meaningfulness Debate
Statistical significance and clinical meaningfulness are different questions. Spielmans and colleagues (2021) reanalyzed the RECONNECT data and raised concerns about the clinical relevance of bremelanotide's effects.[8]
Their analysis found that the desire score improvement, while statistically significant, represented a small absolute change on the measurement scale. The percentage of women who achieved a clinically meaningful response (defined by established thresholds on the outcome measures) was modestly higher in the bremelanotide group than placebo, but the majority of treated women did not reach these thresholds. The distress reduction, while real, was also small in absolute terms.
Mintzes and colleagues (2021) extended this critique, arguing that the regulatory approval of bremelanotide (and flibanserin before it) set a precedent of approving drugs with modest efficacy for conditions where the clinical threshold for meaningful improvement is debatable.[8]
The RECONNECT exit study, which surveyed patients after trial completion, presents a different picture. Koochaki and colleagues (2021) found that women who used bremelanotide reported subjective improvements in desire, arousal, and overall sexual satisfaction that they valued, even when the numerical score changes were modest.[8] Patient-reported experience and statistical effect sizes do not always align.
Kingsberg (2015) framed the challenge well: female sexual response is multivariate, involving desire, arousal, orgasm, satisfaction, and emotional context. No single outcome measure fully captures whether a treatment "works."[4]
Safety: Nausea, Blood Pressure, and the 18% Dropout
The side effect profile of bremelanotide is dominated by nausea. Across the Phase 3 trials, 40% of women in the bremelanotide group experienced nausea compared to 1% on placebo. Flushing occurred in 20%, headache in 11%, and injection site reactions in 5%. The overall discontinuation rate due to adverse events was 18% for bremelanotide vs. 2% for placebo.[6]
Clayton and colleagues (2022) reviewed the safety profile across the entire clinical development program and found that nausea was most common with initial doses and tended to decrease with continued use.[11] Long-term safety data from Simon and colleagues (2019) over 52 weeks showed no new safety signals, with the nausea rate declining over time.[7]
Bremelanotide transiently increases blood pressure (average 2-3 mmHg systolic) and decreases heart rate for several hours after injection.[11] The FDA labeling includes a warning for patients with uncontrolled hypertension or cardiovascular disease. For context on melanocortin-mediated cardiovascular effects, see Melanocortin Peptides and Blood Pressure: The Hypertensive Risk.
The practical reality is that a drug taken before sex that makes 40% of users nauseated faces an inherent adoption barrier, regardless of its efficacy on desire scores.
Kisspeptin: Brain Imaging Points to a New Target
Kisspeptin is a neuropeptide that controls the reproductive hormone cascade by stimulating GnRH neurons in the hypothalamus. Its role in sexual behavior was identified more recently, through functional brain imaging studies showing that kisspeptin modulates how the brain processes sexual stimuli.
Mills and colleagues (2022) conducted a randomized, placebo-controlled, crossover trial in 32 premenopausal women with HSDD. Participants received intravenous kisspeptin or placebo while undergoing functional MRI during exposure to erotic video stimuli.[9]
Kisspeptin deactivated brain regions involved in self-monitoring and self-judgment (specifically the left inferior frontal gyrus) while increasing activity in sexual arousal centers (the right postcentral and supramarginal gyrus). Women reported feeling more "sexy" after kisspeptin administration. The effects were observed acutely, during the infusion, suggesting a direct central action on sexual brain processing.[9]
Kisspeptin was well tolerated with no reported adverse effects in this trial. The mechanism, reducing inhibitory self-monitoring while enhancing arousal processing, is conceptually appealing for HSDD, where excessive cognitive inhibition of desire is considered a key component.
The limitations are substantial. The trial was small (32 women), acute (single infusion), and measured brain activity rather than real-world sexual outcomes. Kisspeptin's short half-life (minutes) makes it impractical as a take-home therapy without formulation changes. No Phase 2 or Phase 3 trials in HSDD have been announced. Kisspeptin for female sexual function remains a proof-of-concept, not a therapy.
Oxytocin: Mixed Results for Sexual Function
Oxytocin is released during orgasm and physical touch, and plasma levels correlate with subjective sexual arousal.[1] This association has driven interest in exogenous oxytocin as a treatment for sexual dysfunction.
Muin and colleagues (2015) conducted a randomized trial of long-term intranasal oxytocin in women with sexual dysfunction, comparing premenopausal and postmenopausal groups. Premenopausal women showed improvement in sexual function scores with oxytocin treatment. Postmenopausal women did not.[5]
The divergent results by menopausal status suggest that oxytocin's effects on sexual function depend on the underlying hormonal environment. Estrogen modulates oxytocin receptor expression, and the postmenopausal decline in estrogen may reduce the ability of exogenous oxytocin to influence sexual response.
Other studies of intranasal oxytocin for sexual function have produced inconsistent results. Behnia and colleagues (2014) found that intranasal oxytocin had differential effects on sexual experiences in couples, with some measures improving and others unchanged.[5] The variability may reflect oxytocin's complex role: it enhances bonding and trust but does not directly stimulate desire pathways in the way melanocortins or kisspeptin do.
Oxytocin is not a candidate for FDA approval as a sexual dysfunction treatment in its current form. Its effects are too inconsistent and too dependent on context (relationship quality, hormonal status, setting) to produce the kind of reproducible efficacy data regulators require.
How These Peptides Compare
| Feature | Bremelanotide | Kisspeptin | Oxytocin |
|---|---|---|---|
| Approval status | FDA approved (2019) | Preclinical/Phase 1 | Not in trials for FSD |
| Target | MC3R/MC4R | Kiss1R/GnRH neurons | Oxytocin receptors |
| Mechanism | Increases dopamine in desire circuits | Reduces self-inhibition, enhances arousal processing | Enhances bonding, variable effects on desire |
| Route | Subcutaneous injection | IV infusion (research only) | Intranasal spray |
| Key side effect | Nausea (40%) | None reported | Inconsistent efficacy |
| Evidence level | Two Phase 3 RCTs (n=1,247) | One crossover RCT (n=32) | Small, mixed-result trials |
What the Pipeline Holds
The melanocortin pathway remains the most clinically validated peptide target for female sexual dysfunction. Pfaus (2022) reviewed the neurobiology of bremelanotide's effects and identified potential for more selective MC4R agonists that might improve the efficacy-to-side-effect ratio by avoiding MC3R activation.[10]
Kisspeptin analogs with longer half-lives are being developed for reproductive medicine applications (IVF, hypogonadism), and their effects on sexual function could be studied as secondary endpoints in those trials. The mechanistic rationale is strong: reducing self-inhibitory brain processing while enhancing arousal circuits addresses a core feature of HSDD.
Combination approaches, using peptides alongside psychotherapy or hormonal treatments, have not been formally tested but represent a logical next step. HSDD involves biological, psychological, and relational factors. A peptide that modulates brain desire circuits combined with therapy that addresses the psychological components could produce effects that neither achieves alone.
For context on how bremelanotide's mechanism works at the receptor level, see How Bremelanotide Works: A Central Nervous System Approach to Desire.
The Bottom Line
Bremelanotide is the only FDA-approved peptide for female sexual dysfunction, with Phase 3 data showing statistically significant but modestly sized improvements in desire and distress in premenopausal women with HSDD. Nausea affects 40% of users. Kisspeptin showed promising brain imaging results in a small RCT, reducing self-inhibitory processing and enhancing sexual arousal circuits, but is years from clinical application. Oxytocin has produced mixed results in sexual function trials, with efficacy varying by menopausal status and study design. All three peptides work through central nervous system mechanisms, a fundamentally different approach than blood flow-based treatments for male sexual dysfunction.